CME/CE

Episodes 65-74 of 74

• 

  RestartResume

  Managing patients with HCM and HF: what’s new in the therapeutic landscape?

  RestartResume

  Managing patients with HCM and HF: what’s new in the therapeutic landscape?

  MinuteCE®

  Managing patients with HCM and HF: what’s new in the therapeutic landscape?

  1.00 program credit

  • 

    

    Iacopo Olivotto, MD

  1.00 program credit

• 

  RestartResume

  Primary care role in CKD

  RestartResume

  Primary care role in CKD

  MinuteCE®

  Primary care role in CKD

  1.00 program credit

  • 

    

    Richard Hobbs, MD

  1.00 program credit

• 

  RestartResume

  What is the evidence of SGLT2i in CKD?

  RestartResume

  What is the evidence of SGLT2i in CKD?

  MinuteCE®

  What is the evidence of SGLT2i in CKD?

  1.00 program credit

  • 

    

    Hiddo L. Heerspink, PhD

  1.00 program credit

• 

  MinuteCE®

  4 things to know about CKD and SGLT2i

  1.00 credit 4 episodes

  • 

    

    Hiddo L. Heerspink, PhD

  • 

    

    David Wheeler, MB, CHB, MD, FRCP

  • 

    

    Meg Jardine, MD, PhD

  • 

    

    Richard Hobbs, MD

  1.00 credit 4 episodes

• 

  RestartResume

  A call to action: optimizing treatment in CKD

  RestartResume

  A call to action: optimizing treatment in CKD

  MinuteCE®

  A call to action: optimizing treatment in CKD

  1.00 program credit

  • 

    

    Meg Jardine, MD, PhD

  1.00 program credit

• 

  RestartResume

  When and how to initiate SGLT2i in CKD

  RestartResume

  When and how to initiate SGLT2i in CKD

  MinuteCE®

  When and how to initiate SGLT2i in CKD

  1.00 program credit

  • 

    

    David Wheeler, MB, CHB, MD, FRCP

  1.00 program credit

• 

  RestartResume

  Mechanistic clues to understanding the benefits of icosapent ethyl
  

  RestartResume

  Mechanistic clues to understanding the benefits of icosapent ethyl
  

  MinuteCE®

  Mechanistic clues to understanding the benefits of icosapent ethyl
  

  1.00 program credit

  • 

    

    Matthew Jay Budoff, MD

  1.00 program credit

• 

  RestartResume

  Addressing late-breaking data on triglycerides, fibrates and omega-3 FAs
  

  RestartResume

  Addressing late-breaking data on triglycerides, fibrates and omega-3 FAs
  

  MinuteCE®

  Addressing late-breaking data on triglycerides, fibrates and omega-3 FAs
  

  1.00 program credit

  • 

    

    Peter Libby, MD

  • 

    

    P. Gabriel Steg, MD

  • 

    

    Prof. Kausik Ray, MBChB, MD, MPhil

  1.00 program credit

• 

  MinuteCE®

  Tackling risk reduction in ASCVD: Sharing international experience

  1.00 credit 3 episodes

  • 

    

    Matthew Jay Budoff, MD

  • 

    

    Lawrence A. Leiter, MD

  • 

    

    Peter Libby, MD

  • 

    

    P. Gabriel Steg, MD

  • 

    

    Prof. Kausik Ray, MBChB, MD, MPhil

  1.00 credit 3 episodes

• 

  RestartResume

  Tackling risk reduction in ASCVD: A clinical case  
  

  RestartResume

  Tackling risk reduction in ASCVD: A clinical case  
  

  MinuteCE®

  Tackling risk reduction in ASCVD: A clinical case  
  

  1.00 program credit

  • 

    

    Lawrence A. Leiter, MD

  1.00 program credit